Anti-Tumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination With Enzalutamide in Prostate Cancer Models

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-19-0378
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Early Evidence of Anti-Pd-1 Activity in Enzalutamide-Resistant Prostate Cancer

Oncotarget
Oncology
2016English

Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer

Genes and Cancer
Cancer ResearchGenetics
2013English

Anti-Igf-1r Monoclonal Antibody Inhibits the Carcinogenicity Activity of Acquired Trastuzumab-Resistant SKOV3

Journal of Ovarian Research
GynecologyOncologyObstetrics
2014English

R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis

PLoS ONE
Multidisciplinary
2011English

Early Developmental Changes in IGF-I, IGF-II, IGF Binding Protein-1, and IGF Binding Protein-3 Concentration in the Cerebrospinal Fluid of Children

Pediatric Research
Child HealthPediatricsPerinatology
2005English

IGF-1 Is Downregulated in Experimental Cancer Cachexia

American Journal of Physiology - Regulatory Integrative and Comparative Physiology
Physiology
2006English

Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination With Anti-Igf Signaling Agents

Clinical Cancer Research
Cancer ResearchOncology
2015English

IGF-1 Receptor and IGF Binding Protein-3 Might Predict Prognosis of Patients With Resectable Pancreatic Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Plasma Androgens, IGF-1, Body Size, and Prostate Cancer Risk: A Synthetic Review

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy